Generic Supply Chain | Association for Accessible Medicines
New Blog - Jonathan Kimball gives more detail re: AAM's blueprint & proposed policy framework

Generic Supply Chain

AAM Statement on Senate Finance Hearing on FDA’s Foreign Manufacturing Inspection Process

WASHINGTON, DC (June 2, 2020) — The COVID-19 crisis exposed many shortcomings in our health care system’s ability to respond to a pandemic. At the same time, many parts of that same system — including the supply chain for the vast majority of generic medicines — demonstrated extraordinary resiliency in the face of unprecedented stresses.

A Blueprint for Enhancing the Security of the U.S. Pharmaceutical Supply Chain

Introduction

A closely connected, diverse and resilient pharmaceutical supply chain based in the United States and in U.S. allied countries (for example, Canada, Europe, India, Israel and Jordan) is the best means to ensure that U.S. patients and the U.S. health care system have access to a secure and consistent supply of critical pharmaceuticals.

AAM Releases Blueprint for Enhancing the Security of the U.S. Pharmaceutical Supply Chain

WASHINGTON, DC (April 30, 2020) — The Association for Accessible Medicines today released “A Blueprint for Enhancing the Security of the U.S. Pharmaceutical Supply Chain,” a six-element framework that lays out concrete actions that the federal government could take to ensure that U.S. patients and the U.S. health care system have access to a secure and consistent supply of critical pharmaceuticals.

COVID-19 Response: Anthony Maffia at Sandoz

Anthony Maffia works in New Jersey at Sandoz as Vice President, Head of Regulatory Affairs, North America.

AAM is recognizing dedicated people like Anthony and his peers across the generic & biosimilar industry who show up each day for US patients.

The industry is "finding new and creative and rapid ways to get medication into the hands of patients that need it.”

Subscribe to Generic Supply Chain

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.